tracken
Amicus Therapeutics, Inc. Aktie News
Neutral
GlobeNewsWire
●
2 Monate alt
2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year Strong Patient Demand Continues for Pombiliti ™ + Opfolda ™ in the U.S., U.K., and Germany Projecting 2024 Galafold ® Revenue Growth of 11-16% at CER Anticipating Full-Year Non-GAAP Profitability in 2024 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J.
Neutral
GlobeNewsWire
●
3 Monate alt
PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 2024, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2023.
Neutral
GlobeNewsWire
●
3 Monate alt
- Award Recognizes Approval of Amicus Therapeutics' Two-component Therapy for the Treatment of Late-onset Pompe Disease - - Award Recognizes Approval of Amicus Therapeutics' Two-component Therapy for the Treatment of Late-onset Pompe Disease -
Neutral
GlobeNewsWire
●
3 Monate alt
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11 posters across its development programs will be included at the 20th Annual WORLDSymposium™ 2024, being held February 4-9, 2024 in San Diego, CA.
Positiv
MarketBeat
●
4 Monate alt
The new year brings a clean slate heading into the fourth-quarter earnings season. Companies can usually gauge if their previous forecasts were in line or need to be adjusted to warn or prepare investors ahead of time.
Neutral
GlobeNewsWire
●
4 Monate alt
2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year >2,400 People Living with Fabry Disease on Galafold ® Following a Year of Increased Demand Expecting 2024 Galafold Revenue Growth of 11-16% at CER Successful Launches of Pombiliti ™ + Opfolda ™ Underway in the U.S., U.K., and Germany PRINCETON, N.J., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedi...
Neutral
GlobeNewsWire
●
4 Monate alt
PRINCETON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8, 2024, at 2:15 p.m. PT.
Neutral
GlobeNewsWire
●
5 Monate alt
Crowley to Step Down from Amicus Board of Directors in March 2024 and Become Amicus Chairman Emeritus
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
